Strategies for recombinant production of antimicrobial peptides with pharmacological potential

Oliveira, Kamila Botelho Sampaio de; Leite, Michel Lopes; Rodrigues, Gisele Regina; Duque, Harry Morales; Costa, Rosiane Andrade da; Cunha, Victor Albuquerque; Costa, Lorena S. de Loiola; Cunha, Nicolau Brito da; Franco, Octávio Luiz; Dias, Simoni Campos

doi:10.1080/17512433.2020.1764347

Cited by 31 publications

(22 citation statements)

References 341 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particular attention should be given for those peptides with a broad spectrum of activity. Concerning activity, an ideal compound should have an IC 50 25 µM or 10 µg/mL, whereas for extracts at the initial steps of purification, a standard cut-off should be below 100 µg/mL, similar to the criteria established for natural compounds [204][205][206][207]. In this review, we explored the peptides produced by cyanobacteria and microalgae, mainly as antibacterial, with a special focus on compounds with MIC values below those aforementioned (Table 3), as the most appealing candidates for their further pharmacological development and clinical implementation.…”

Section: Discussionmentioning

confidence: 99%

“…This turn of the tide underlies new strategies to overcome the limitations described above, converting peptides into valuable drug candidates: firstly, the decrease in cost by implementation of more efficient and cheaper strategies of synthesis [43][44][45][46][47] or, alternatively, the development of improved production of recombinant peptides [48][49][50][51]; secondly, the improvement of peptide bioavailability by engineering strategies aimed to prevent proteolytic degradation, either by manipulation of their primary sequence by incorporation of unnatural amino acids [52,53], β and γ amino acid peptides [54,55], enantiomeric peptides [56,57] and peptidomimetics [58][59][60][61], or by acquisition of a more stable conformation that secludes or shields the recognition of the cleavage sequence by peptidases (cyclation [46,62,63] and stapled peptides [64]).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides

et al. 2020

View full text Add to dashboard Cite

Cyanobacteria and microalgae are oxygen-producing photosynthetic unicellular organisms encompassing a great diversity of species, which are able to grow under all types of extreme environments and exposed to a wide variety of predators and microbial pathogens. The antibacterial compounds described for these organisms include alkaloids, fatty acids, indoles, macrolides, peptides, phenols, pigments and terpenes, among others. This review presents an overview of antibacterial peptides isolated from cyanobacteria and microalgae, as well as their synergism and mechanisms of action described so far. Antibacterial cyanopeptides belong to different orders, but mainly from Oscillatoriales and Nostocales. Cyanopeptides have different structures but are mainly cyclic peptides. This vast peptide repertoire includes ribosomal and abundant non-ribosomal peptides, evaluated by standard conventional methodologies against pathogenic Gram-negative and Gram-positive bacteria. The antibacterial activity described for microalgal peptides is considerably scarcer, and limited to protein hydrolysates from two Chlorella species, and few peptides from Tetraselmis suecica. Despite the promising applications of antibacterial peptides and the importance of searching for new natural sources of antibiotics, limitations still persist for their pharmaceutical applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Open Sci. 9: 211583 amino acids and vectors used [266,267]. Moreover, the high expression of AMPs could induce a killing effect on yeast and bacteria, thus resulting in a low yield and endotoxin release [268].…”

Section: Production Of Commercial Antimicrobial Peptidesmentioning

confidence: 99%

“…Therefore, it is suggested that chemical technology is more suitable for human use with high purity requirements, especially for producing AMPs with non-canonical amino acids and other chemical modifications. In addition, recombinant technology is widely applied for veterinary, animal growth aid and plant protection owing to the balance between cost and efficacy [ 243 , 267 , 269 ].…”

Section: Production Of Commercial Antimicrobial Peptidesmentioning

confidence: 99%

Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance

et al. 2022

View full text Add to dashboard Cite

In the last century, conventional antibiotics have played a significant role in global healthcare. Antibiotics support the body in controlling bacterial infection and simultaneously increase the tendency of drug resistance. Consequently, there is a severe concern regarding the regression of the antibiotic era. Despite the use of antibiotics, host defence systems are vital in fighting infectious diseases. In fact, the expression of ribosomal antimicrobial peptides (AMPs) has been crucial in the evolution of innate host defences and has been irreplaceable to date. Therefore, this valuable source is considered to have great potential in tackling the antimicrobial resistance (AMR) crisis. Furthermore, the possibility of bacterial resistance to AMPs has been intensively investigated. Here, we summarize all aspects related to the multiple applications of ribosomal AMPs and their derivatives in combating AMR.

show abstract

“…Clinical implementation of AMPs is still a challenging area [28,43]. They are relatively safe due to their nature, but improved extraction and stability, low yield in recombinant heterologous expression [44], negligible toxicity expectantly in organoids and other 3D cellular models [45], and lowering the costs needs to be assessed, including the engineered synthetic production as inspired by nature. Only a few AMPs are studied in ongoing clinical trials [46], but they are currently seen as promising candidates and future alternative to conventional antibiotics [47].…”

Section: Renewing Antimicrobial Peptides Potentialmentioning

confidence: 99%

Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome

Marrazzo

Pizzuti

Zia³

et al. 2021

Antibiotics

View full text Add to dashboard Cite

Antibiotic resistance is creating enormous attention on the development of new antibiotic-free therapy strategies for bacterial diseases. Mesenchymal stromal stem cells (MSCs) are the most promising candidates in current clinical trials and included in several cell-therapy protocols. Together with the well-known immunomodulatory and regenerative potential of the MSC secretome, these cells have shown direct and indirect anti-bacterial effects. However, the low reproducibility and standardization of MSCs from different sources are the current limitations prior to the purification of cell-free secreted antimicrobial peptides and exosomes. In order to improve MSC characterization, novel label-free functional tests, evaluating the biophysical properties of the cells, will be advantageous for their cell profiling, population sorting, and quality control. We discuss the potential of emerging microfluidic technologies providing new insights into density, shape, and size of live cells, starting from heterogeneous or 3D cultured samples. The prospective application of these technologies to studying MSC populations may contribute to developing new biopharmaceutical strategies with a view to naturally overcoming bacterial defense mechanisms.

show abstract

Strategies for recombinant production of antimicrobial peptides with pharmacological potential

Cited by 31 publications

References 341 publications

Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides

Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides

Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance

Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome

Contact Info

Product

Resources

About